Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$1,057.02 5.99 (0.57%) as of 4:30 Mon 7/1


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 110.66(B)
Last Volume: 383,195 Avg Vol: 759,306
52 Week Range: $692.45 - $1071.19
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 192,108 255,165 311,759 469,743
Total Sell Value $188,697,290 $247,812,013 $294,950,701 $405,465,351
Total People Sold 7 14 16 18
Total Sell Transactions 18 43 67 128
End Date 2024-03-31 2023-12-29 2023-06-30 2022-06-30

   
Records found: 2430
  Page 60 of 98  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2013-12-31 4 OE $30.63 $1,470,240 D/D 48,000 73,447     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2013-12-24 4 OE $21.25 $99,981 D/D 4,705 25,447     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2013-12-20 4 AS $271.09 $36,055 D/D (133) 20,742     -
   Yancopoulos George President Regeneron Laboratori   •       •      –    2013-12-19 4 OE $21.25 $99,981 D/D 4,705 1,068,343     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2013-12-18 4 D $264.86 $42,907 D/D (162) 20,875     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2013-12-18 4 OE $21.25 $6,269 D/D 295 21,037     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2013-12-18 4 AS $270.20 $2,431,800 D/D (9,000) 20,742     -
   Stahl Neil SVP Research and Development S   •       –      –    2013-12-18 4 OE $21.25 $99,981 D/D 4,705 24,391     -
   Goldberg Murray A SVP Administration & Asst Secr   •       –      –    2013-12-18 4 OE $21.25 $99,981 D/D 4,705 63,102     -
   Terifay Robert J SVP Commercial   •       –      –    2013-12-18 4 OE $21.25 $99,981 D/D 4,705 20,029     -
   Van Plew Daniel P SVP & General Mgr Industrial O   •       –      –    2013-12-18 4 OE $21.25 $99,981 D/D 4,705 15,441     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2013-12-17 4 AS $270.00 $2,160 D/D (8) 29,742     -
   Stahl Neil SVP Research and Development S   •       –      –    2013-12-16 4 D $272.73 $2,536,934 D/D (9,302) 19,686     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2013-12-16 4 D $272.73 $5,895,604 D/D (21,617) 29,750     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2013-12-16 4 OE $30.63 $3,281,056 D/D 30,625 34,310     -
   Yancopoulos George Pres Regeneron Labs   •       •      –    2013-12-16 4 D $272.73 $11,720,299 D/D (42,974) 1,063,638     -
   Goldberg Murray A SVP Administration & Asst Secr   •       –      –    2013-12-16 4 D $272.73 $1,406,469 D/D (5,157) 58,397     -
   Yancopoulos George Pres Regeneron Labs   •       •      –    2013-12-12 4 D $273.06 $2,561,849 D/D (9,382) 1,106,612     -
   Yancopoulos George Pres Regeneron Labs   •       •      –    2013-12-12 4 OE $260.44 $2,499,964 D/D 9,599 1,115,994     -
   Vagelos P Roy Chairman of the Board   •       •      –    2013-12-02 4 S $296.11 $28,130 I/I (95) 2,257     -
   Baker Charles A Director   –       •      –    2013-11-26 4 GD $0.00 $0 I/I 590 0     -
   Shooter Eric M Director   –       •      –    2013-11-26 4 GD $0.00 $0 I/I 8,185 0     -
   Shooter Eric M Director   –       •      –    2013-11-26 4 A $0.00 $0 I/I 8,185 8,185     -
   Sing George L Director   –       •      –    2013-11-26 4 S $295.00 $2,950,000 D/D (10,000) 112,772     -
   Sing George L Director   –       •      –    2013-11-26 4 OE $15.01 $150,100 D/D 10,000 122,772     -
  2430 Records found
  Previous  60  61  62  63  64  65  66  67  68  69  Next   
  Page 60 of 98
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us